L

Leben Salud | Fundacion Medica de Rio Negro y Neuquen

Research site

(Unclaimed)

Location

47 Irigoyen Street, Cipolletti, Rio Negro, Argentina

Site insights

Top conditions

Top treatments

Durvalumab

Platinum

Etoposide

Bemarituzumab

Pembrolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 3 total trials

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS...

Active, not recruiting

Small-Cell Lung Cancer

Extensive-Stage Small-Cell Lung Cancer

Drug: Tarlatamab

Drug: Durvalumab

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (Be6A Lung-02)

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alon...

Enrolling

Carcinoma, Non-Small-Cell Lung (NSCLC)

Carcinoma, Non-Small-Cell Lung

Drug: Pembrolizumab

Drug: Sigvotatug Vedotin

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms